House Energy and Commerce Committee leaders yesterday sent letters to nine contract pharmacies that participate in the 340B drug savings program requesting information about their participation in the program. The letters sought information on contracting practices; the distance between covered entities and contract pharmacies; to what degree contract pharmacies prevent duplicate discounts or diversion in the program; and whether contract pharmacies ensure low-income uninsured patients do not face high drug costs despite the program’s discount. The letters follow a June Government Accountability Office report recommending that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B requirements.
 

Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…
Headline
The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled…